The continuous glucose monitoring market encompasses the medical technology sector focused on wearable devices that track blood sugar levels in real time throughout the day and night via a sensor inserted under the skin. It primarily serves individuals with diabetes to enable proactive glycemic control, trend analysis, and automated insulin delivery integration. CGM Market
The global blood glucose monitoring system market was valued at USD 15.16 billion in 2024 and USD 16.46 billion in 2025, and it is projected to reach USD 25.41 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.1%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14912252
The continuous glucose monitoring (CGM) market is primarily driven by the escalating global prevalence of diabetes, rapid advancements in wearable sensor technology, and a growing demand for remote patient monitoring and personalized medicine. However, market expansion is heavily restrained by the high cost of devices and ongoing sensor replacements, which limits accessibility in developing regions lacking comprehensive health insurance coverage. Lucrative opportunities exist in the recent regulatory approvals for over-the-counter devices that target broader wellness segments for preventive health, alongside the integration of glucose data with automated insulin delivery and digital health platforms. Despite these prospects, the industry faces key challenges, including upward cost pressures from manufacturing complex data analytics hardware, the proliferation of lower-cost refurbished systems, and potential patient hurdles like information overload and user anxiety.
The target customers for the continuous glucose monitoring (CGM) market comprise a diverse mix of clinical patients and health-conscious consumer segments, including Type 1 and intensive Type 2 diabetics, non-intensive Type 2 patients, pre-diabetic individuals, pediatric cohorts, and wellness enthusiasts like biohackers. Clinical users prioritize high data accuracy, discreet device profiles, customizable predictive safety alarms for hypoglycemia prevention, and seamless integration with insulin pumps and digital health stacks like smartwatches. Meanwhile, wellness and non-diabetic consumers value over-the-counter accessibility, affordability, and user-friendly platforms to track real-time metabolic responses to diet, exercise, stress, and sleep. Purchasing behavior is heavily shaped by healthcare provider recommendations and expanding insurance or Medicare coverage for traditional clinical demographics, whereas consumer wellness segments demonstrate a strong preference for direct-to-consumer online pharmacies, out-of-pocket spending, and subscription-based retail models that prioritize convenience and proactive lifestyle optimization.
Market entry, expansion, and profitability in the Continuous Glucose Monitoring (CGM) market are heavily shaped by evolving regulatory pathways, rapid technological innovation, and distinct economic pressures. Regulatory approvals, such as CE Marks and FDA clearances for over-the-counter devices, open substantial expansion opportunities, though compliance requirements remain strict. Technologically, the market is being disrupted by advancements in sensor accuracy, miniaturization, integration with automated insulin delivery (closed-loop) systems, and the shift toward AI-enabled data analytics and smartphone connectivity (Bluetooth and NFC). Economically, while high global diabetes prevalence ensures sustained demand, profitability and widespread adoption face significant restraints from the high recurring cost of sensors, upward pressure on manufacturing expenditures for complex hardware, and uneven insurance or reimbursement coverage, particularly in developing and price-sensitive emerging markets where refurbished equipment also presents competition.
The continuous glucose monitoring (CGM) market is experiencing rapid transformation driven by key emerging trends, including the miniaturization of sensors, the integration of non-invasive and minimally invasive prototypes, and the convergence of devices with advanced healthcare software. A major shift is occurring toward over-the-counter (OTC) continuous glucose monitors, expanding use cases from strictly medical necessity into broader consumer wellness, preventive health, and precision titration alongside GLP-1 therapies. These trends are evolving swiftly, highlighted by robust double-digit market growth rates—such as projected compound annual growth rates (CAGRs) ranging between 12% and 16.3% over the next decade—alongside the rapid development of late-stage implantable 365-day sensors and the establishment of recurring revenue streams through digital analytics subscriptions.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=14912252
Technological innovations disrupting the continuous glucose monitoring (CGM) market are centered on increased personalization, convenience, and expanded analytical capabilities. The industry is witnessing a significant shift toward automated insulin delivery (AID) systems, commonly known as artificial pancreas systems, which integrate CGM sensors directly with algorithm-driven insulin pumps to automate insulin dosing. Additionally, next-generation sensor designs are gaining rapid traction, including research into implantable sensors for extended longevity and minimally invasive or completely non-invasive prototypes like optical, electromagnetic, and bioimpedance surface sensors. Innovation is also expanding through the convergence of CGM devices with artificial intelligence (AI) and machine learning (ML) predictive modeling platforms, which analyze vast amounts of real-time data to anticipate glucose fluctuations and offer tailored dietary and insulin recommendations.
In the continuous glucose monitoring market, short-term hype is primarily visible around early-stage, completely non-invasive optical tracking concepts and intensive social media promotions for consumer wellness and generic fitness tracking, which often outpace current clinical reliability and regulatory approvals. Conversely, long-term structural shifts are firmly anchored in medical-grade infrastructure and precision health management. These enduring transformations include the convergence of hardware with digital analytics subscriptions that establish recurring revenue models, the integration of continuous glucose data with GLP-1 therapy for exact dosage titration, expanding public and private insurance frameworks (such as expanded Medicare coverage), and the steady transition of sensors into the standard of care for intensive insulin-dependent populations alongside the emerging expansion into proactive homecare and over-the-counter wellness applications.
